Catalyst Event
Sanofi (SNY) · Other
From KEDI Nvidia Fixed Tech100 Index (KNVDT100)
4/13/2026, 12:00:00 AM
On April 13, 2026, the European Commission approved Dupixent (dupilumab), developed with Regeneron, to treat children aged 2 to 11 with moderate-to-severe chronic spontaneous urticaria (CSU).
Korean Translation
2026년 4월 13일, 유럽 위원회는 리제네론과 공동 개발한 듀피젠트(두필루맙)를 2세에서 11세 사이의 중등도에서 중증의 만성 특발성 두드러기(CSU) 소아 환자 치료제로 승인함.
Related Recent Events
Credo Technology Group Holding Ltd (CRDO) · Earnings Release
Q4 and Full Fiscal Year 2026 earnings release on 2026-06-01 expected. Analysts forecast EPS around $0.93 and revenue of approximately $431 million forecasted. Earnings releases typically cause 5-10% price movement.
6/1/2026, 12:00:00 AM
Marvell Technology Inc (MRVL) · Earnings Release
First quarter fiscal year 2027 earnings results are scheduled to be released on May 29, 2026. Market impact is estimated at >1% as earnings releases typically drive volatility scheduled.
5/29/2026, 12:00:00 AM
Analog Devices Inc (ADI) · Earnings Release
Analog Devices is expected to release its fiscal second quarter 2026 financial results around late May. The date is estimated based on previous reporting schedules and is scheduled.
5/28/2026, 12:00:00 AM
Axon Enterprise Inc (AXON) · Other
Axon's Annual Meeting of Shareholders on 2026-05-28 where director Matthew McBrady will not seek re-election, which is estimated to have low importance as board changes are common, is scheduled.
5/28/2026, 12:00:00 AM
NVIDIA Corporation (NVDA) · Earnings Release
NVIDIA Q1 FY2027 earnings release and conference call scheduled. Low importance is estimated as a date announcement typically has >=1% price impact.
5/27/2026, 12:00:00 AM
Synopsys Inc (SNPS) · Earnings Release
Low importance estimated as market impact is pending results; Q2 2026 earnings release is scheduled.
5/27/2026, 12:00:00 AM